De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations
- 5 February 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 74 (2) , 1003-1013
Abstract
Background and Aims: Gastrointestinal (GI) malignancies are common after liver transplantation. The aim of this study was to identify the risk and timing of the more common GI malignancies, colorectal and pancreatic cancer, to aid in optimizing potential posttransplant screening practices. Approach and Results: Data from the United Network for Organ Sharing database of all adult liver‐transplant recipients from 1997 to 2017 were analyzed and a comparison made with cancer incidence from general population data using Surveillance, Epidemiology, and End Results data. Of 866 de novo GI malignancies, 405 colorectal and 216 pancreas were identified. The highest cumulative incidence for colorectal cancer occurred in recipients with primary sclerosing cholangitis (PSC), recipients over the age of 50 with non‐alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)/cholangiocarcinoma (CCA), and females >50 years with alcohol‐associated liver disease and HCC/CCA, with risk increasing above the general population within 5 years of transplant. Patients with PSC and HCC/CCA or NASH and HCC/CCA have the highest cumulative incidence of pancreatic cancer also rising within 5 years following transplant, with those patients >50 years old conferring the highest risk. Conclusions: These data identify a high‐risk cohort that warrants consideration for intensified individualized screening practices for colorectal cancer after liver transplantation. In addition to recipients with PSC, further study of recipients with NASH and HCC/CCA and females with alcohol‐associated liver disease and HCC/CCA may be better tailored to colorectal cancer screening ideals. Higher‐risk patient populations for pancreatic cancer (PSC and NASH with HCC/CCA) would benefit from further study to determine potential screening practices. GI malignancies occur at higher rates in liver‐transplant patients compared with the general population. In the era of individualized medicine, this study identifies the highest‐risk transplant recipients (PSC and NASH cirrhosis with coexisting HCC/CCA) who may benefit from altered screening practices for these malignancies.Keywords
This publication has 25 references indexed in Scilit:
- Screening for Pancreatic CancerAnnals of Surgery, 2013
- Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long‐term single‐centre studyLiver International, 2011
- Prevalence of multiple malignancies in the Netherlands in 2007International Journal of Cancer, 2011
- Risk of Development of the Metabolic Syndrome After Orthotopic Liver TransplantationTransplantation Proceedings, 2010
- Long-term Probability of and Mortality From De Novo Malignancy After Liver TransplantationGastroenterology, 2009
- Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infectionHepatology, 2008
- Gender differences in colorectal cancer screening barriers and information needs1Health Expectations, 2007
- Characteristics and Survival Patterns of Solid Organ Transplant Patients Developing De Novo Colon and Rectal CancerDiseases of the Colon & Rectum, 2004
- Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitisTransplantation, 2003
- Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantationHepatology, 1998